Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator dictionary.testing.TypeOfStudy dictionary.testing.PhasesOfClinicalTrialsForDrugs
N202506023 RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC New Drug Phase Ⅲ
N202506024 EASi-HF reduced – A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% New Drug Phase Ⅲ
N202506029 New Medical Procedure: Evaluation of silver diamine fluoride (SDF) in preventing early childhood caries (ECC) and its staining in the primary teeth New Medical Technology NA
N202506038 A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA) New Drug Phase Ⅱ
N202506046 An Exploratory Study to Identify Optimal Indication Criteria for The Use of Immunomodulatory Therapy in Patients with Kawasaki Disease New Drug (New Indication) Academic Research
N202506047 PERIS: Prospective multi-country, real-world, multi-arm study of treatment PErsistence with RISankizumab in Psoriatic Arthritis New Drug PMS(Post Marketing Surveillance)
1 2 26 27 28 29 30 31 32 51 52 / 52

TOP